Clarus Therapeutics, Inc. v. Lipoline, Inc., No.
19-1566, Courtroom 402 (telephonic argument)
Lipoline initiated an interference proceeding on Clarus's
patent under 35 U.S.C. § 135(a). Lipoline argued to the
Patent Trial and Appeal Board (“PTAB”) that
Clarus's patent cannot claim a priority date to a provisional
application, because the provisional application did not provide
sufficient written description support for the claimed formulation.
The PTAB granted Lipoline's motion on the priority date.
Then, Lipoline convinced the PTAB that its own invention date
preceded the patent's priority date. As a result, the PTAB
revoked Clarus's patent.
On appeal, Clarus argues that the provisional application
provides at least one anticipatory embodiment of the claim,
allowing a person of ordinary skill in the art (“POSA”)
to recognize that the inventor invented what is claimed. More
specifically, Clarus argues that to provide support for the claimed
negative limitation at